Ginspire Early Discovery Platform

SHANGHAI, Oct. 13, 2025 /PRNewswire/ -- Thousand Oaks Biologics' antibody-drug conjugate (ADC) manufacturing site successfully passed an audit conducted by a European Union Qualified Person (QP) and formally received a QP Declaration. This milestone certifies that the company's quality management system and commercial production capability in the field of antibody-drug conjugates (ADCs) comply with EU Good Manufacturing Practice (GMP) standards, positioning Thousand Oaks Biologics Shanghai as one of the few CDMOs in China offering end-to-end international ADC services.

Thousand Oaks Biologics Inc. (TOBio), a premier Integrated CMC Solution Provider, focuses on comprehensive solutions for large - scale, compliant biopharmaceutical production. Its business covers three main segments: Biopharmaceutical CDMO, Cell Culture Medium, and Early - Stage Research Services. Its products and technical services find extensive applications in the production of recombinant proteins, antibody - based drugs, human and veterinary vaccines, and cell therapy products.